A detailed history of Jane Street Group, LLC transactions in Allovir, Inc. stock. As of the latest transaction made, Jane Street Group, LLC holds 83,351 shares of ALVR stock, worth $36,674. This represents 0.0% of its overall portfolio holdings.

Number of Shares
83,351
Previous 173,031 51.83%
Holding current value
$36,674
Previous $124,000 45.97%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.7 - $0.82 $62,775 - $73,537
-89,680 Reduced 51.83%
83,351 $67,000
Q2 2024

Aug 14, 2024

BUY
$0.72 - $0.82 $124,582 - $141,885
173,031 New
173,031 $124,000
Q4 2023

Feb 14, 2024

BUY
$0.68 - $2.39 $10,438 - $36,688
15,351 Added 31.73%
63,727 $43,000
Q3 2023

Nov 14, 2023

BUY
$2.15 - $3.64 $104,008 - $176,088
48,376 New
48,376 $104,000
Q1 2023

May 15, 2023

SELL
$3.94 - $7.05 $27,910 - $49,942
-7,084 Reduced 30.99%
15,774 $62,000
Q4 2022

Feb 14, 2023

SELL
$4.7 - $9.98 $20,468 - $43,462
-4,355 Reduced 16.0%
22,858 $117,000
Q3 2022

Nov 14, 2022

SELL
$4.13 - $8.79 $15,830 - $33,692
-3,833 Reduced 12.35%
27,213 $215,000
Q2 2022

Aug 16, 2022

BUY
$3.26 - $7.06 $67,762 - $146,749
20,786 Added 202.59%
31,046 $121,000
Q1 2022

May 17, 2022

BUY
$6.75 - $13.52 $69,255 - $138,715
10,260 New
10,260 $69,000
Q3 2021

Nov 16, 2021

SELL
$16.97 - $25.06 $322,192 - $475,789
-18,986 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$19.44 - $25.06 $369,087 - $475,789
18,986 New
18,986 $375,000
Q4 2020

Feb 17, 2021

SELL
$23.94 - $46.81 $271,168 - $530,216
-11,327 Closed
0 $0
Q3 2020

Nov 17, 2020

BUY
$21.05 - $42.7 $238,433 - $483,662
11,327 New
11,327 $311,000

Others Institutions Holding ALVR

About Allovir, Inc.


  • Ticker ALVR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,063,400
  • Market Cap $40.9M
  • Description
  • Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, ...
More about ALVR
Track This Portfolio

Track Jane Street Group, LLC Portfolio

Follow Jane Street Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jane Street Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Jane Street Group, LLC with notifications on news.